Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data

References

• Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512. doi:10.1111/1471-0528.1464028296146
   PubMed Web of Science ®Google Scholar
• Bulun S. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1365. doi:10.1056/NEJMra120999324088094
   PubMed Web of Science ®Google Scholar
• Catherino WH, Parrott E, Segars J. Proceedings from the National Institute of Child Health and Human Development conference on the Uterine Fibroid Research Update Workshop. Fertil Steril. 2011;95(1):9–12. doi:10.1016/j.fertnstert.2010.08.04920883986
   PubMed Web of Science ®Google Scholar
• Ben-Nagi J, Miell J, Mavrelos D, Naftalin J, Lee C, Jurkovic D. Endometrial implantation factors in women with submucous uterine fibroids. Reprod Biomed Online. 2010;21(5):610–615. doi:10.1016/j.rbmo.2010.06.03920880745
   PubMed Web of Science ®Google Scholar
• Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod. 2010;25(2):418–429. doi:10.1093/humrep/dep39619910322
   PubMed Web of Science ®Google Scholar
• Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:66–73. doi:10.1016/j.bpobgyn.2015.12.00126856931
   PubMed Web of Science ®Google Scholar
• Parazzini F, Tozzi L, Bianchi S. Pregnancy outcome and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:74–84. doi:10.1016/j.bpobgyn.2015.11.01726723475
   PubMed Web of Science ®Google Scholar
• Hervé F, Katty A, Isabelle Q, Céline S. Impact of uterine fibroids on quality of life: a national cross-sectional survey. Eur J Obstet Gynecol Reprod Biol. 2018;229:32–37. doi:10.1016/j.ejogrb.2018.07.03230099225
   PubMed Web of Science ®Google Scholar
• Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):96–102. doi:10.1016/j.ejogrb.2010.05.01220598796
   PubMed Web of Science ®Google Scholar
• Soliman AM, Margolis MK, Castelli-Haley J, Fuldeore MJ, Owens CD, Coyne KS. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. Curr Med Res Opin. 2017;33(11):1971–1978. doi:10.1080/03007995.2017.137210728836862
   PubMed Web of Science ®Google Scholar
• Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211.e1–9. doi:10.1016/j.ajog.2011.12.002
   Web of Science ®Google Scholar
• Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646–1655. doi:10.1056/NEJMcp141102925901428
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106–116. doi:10.1016/j.maturitas.2014.06.00224975954
   PubMed Web of Science ®Google Scholar
• Mais V, Ajossa S, Guerriero S, Mascia M, Solla E, Melis GB. Laparoscopic versus abdominal myomectomy: a prospective, randomized trial to evaluate benefits in early outcome. Am J Obstet Gynecol. 1996;174(2):654–658. doi:10.1016/s0002-9378(96)70445-38623802
   PubMed Web of Science ®Google Scholar
• Jin C, Hu Y, Chen XC, et al. Laparoscopic versus open myomectomy – a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):14–21. doi:10.1016/j.ejogrb.2009.03.00919398260
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. 2014 Available from: https://wayback.archive-it.org/7993/20170404182209/https:/www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm Accessed 331, 2019.
   Google Scholar
• Siedhoff MT, Cohen SL. Tissue extraction techniques for leiomyomas and uteri during minimally invasive surgery. Obstet Gynecol. 2017;130(6):1251–1260. doi:10.1097/AOG.000000000000233429112659
   PubMed Web of Science ®Google Scholar
• Friedman JA, Wong JMK, Chaudhari A, Tsai S, Milad MP. Hysteroscopic myomectomy: a comparison of techniques and review of current evidence in the management of abnormal uterine bleeding. Curr Opin Obstet Gynecol. 2018;30(4):243–251. doi:10.1097/GCO.000000000000047529939852
   PubMed Web of Science ®Google Scholar
• Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209(4):319.e1–319.e20. doi:10.1016/j.ajog.2013.07.017
   Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–686. doi:10.1093/humupd/dmw02327466209
   PubMed Web of Science ®Google Scholar
• Lee BB, Yu SP. Radiofrequency ablation of uterine fibroids: a review. Curr Obstet Gynecol Rep. 2016;5(4):318–324.27917310
   PubMed Web of Science ®Google Scholar
• Hudgens J, Johns DA, Lukes AS, Forstein DA, Delvadia D. 12-month outcomes of the US patient cohort in the SONATA pivotal IDE trial of transcervical ablation of uterine fibroids. Int J Womens Health. 2019;(11):387–394. doi:10.2147/IJWH.S20191231308763
   PubMed Web of Science ®Google Scholar
• Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science. 1965;150(3692):67–69. doi:10.1126/science.150.3692.675833538
   PubMed Web of Science ®Google Scholar
• Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7(5):e36935. doi:10.1371/journal.pone.003693522570742
   PubMed Web of Science ®Google Scholar
• Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006;33(1):59–67. doi:10.1016/j.ogc.2005.12.00116504806
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433–2442. doi:10.1210/en.2009-122520375184
   PubMed Web of Science ®Google Scholar
• Sumitani H, Shozu M, Segawa T, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000;141(10):3852–3861. doi:10.1210/endo.141.10.771911014242
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192–198. doi:10.1016/j.fertnstert.2008.09.06419135657
   PubMed Web of Science ®Google Scholar
• Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):329–332. doi:10.1016/j.ejogrb.2013.09.01024103533
   PubMed Web of Science ®Google Scholar
• Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;10:CD009505.
   Google Scholar
• Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013;288(1):139–148. doi:10.1007/s00404-013-2797-923553194
   PubMed Web of Science ®Google Scholar
• Jiang W, Shen Q, Chen M, et al. Levonorgestrel releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. Steroids. 2014;86:69–78. doi:10.1016/j.steroids.2014.05.00224832215
   PubMed Web of Science ®Google Scholar
• Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Downregulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand. 2010;89(11):1438–1446. doi:10.3109/00016349.2010.51206820955098
   PubMed Web of Science ®Google Scholar
• Ciebiera M, Łukaszuk K, Męczekalski B, et al. Alternative oral agents in prophylaxis and therapy of uterine fibroids-an up-to-date review. Int J Mol Sci. 2017;18(12):pii:E2586. doi:10.3390/ijms18122586
   Web of Science ®Google Scholar
• Bartels CB, Cayton KC, Chuong FS, et al. An evidence-based approach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59(1):30–52. doi:10.1097/GRF.000000000000017126756261
   PubMed Web of Science ®Google Scholar
• Letteri GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL. Efficacy of gonadotropin releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril. 1989;51(6):951–956. doi:10.1016/s0015-0282(16)60724-02498132
   PubMed Web of Science ®Google Scholar
• Paoletti AM, Serra GG, Cagnacci A, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 1996;65(4):707–710.8654625
   PubMed Web of Science ®Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;2:CD000547.
   PubMedGoogle Scholar
• Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015;3:CD010854.
   Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175–1189. doi:10.1016/j.fertnstert.2011.08.02121944187
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307. doi:10.1093/humupd/dmi00215790602
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420. doi:10.1056/NEJMoa110318222296075
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–432. doi:10.1056/NEJMoa110318022296076
   PubMed Web of Science ®Google Scholar
• Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Dev Ther. 2014;8:285–292.
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–173. doi:10.1016/j.fertnstert.2015.09.03226477496
   PubMed Web of Science ®Google Scholar
• Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017;12(3):e0173523. doi:10.1371/journal.pone.017352328267814
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Esmya: new measures to minimise risk of rare but serious liver injury. EMA/355940/2018. 6 1, 2018 Available from: https://www.ema.europa.eu/en/documents/press-release/esmya-new-measures-minimise-risk-rare-serious-liver-injury_en-0.pdf Accessed 413, 2019.
   Google Scholar
• Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs. 2018;27(5):497–505. doi:10.1080/13543784.2018.1471134
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Küpker W, Krapp M, Gehl B, Ludwig M, Diedrich K. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online. 2001;3(1):14–18. doi:10.1016/s1472-6483(10)61957-812513885
   PubMedGoogle Scholar
• Flierman PA, Oberyé JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG. 2005;112(5):638–642. doi:10.1111/j.1471-0528.2004.00504.x15842290
   PubMed Web of Science ®Google Scholar
• Tan O, Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr Opin Obstet Gynecol. 2011;23(4):238–244. doi:10.1097/GCO.0b013e328348a3ce21666463
   PubMed Web of Science ®Google Scholar
• Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J. Recent development of non-peptide GnRH antagonists. Molecules. 2017;22(12):E2188. doi:10.3390/molecules2212218829232843
   PubMed Web of Science ®Google Scholar
• Markham A. Relugolix: first Global Approval. Drugs. 2019;79(6):675–679. doi:10.1007/s40265-019-01105-030937733
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of OBE2109 in subjects with heavy menstrual bleeding associated with uterine fibroids (PRIMROSE 1). Available from: https://clinicaltrials.gov/ct2/show/NCT03070899?view=record ClinicalTrials.gov Identifier: NCT03070899. Accessed 414, 2019.
   Google Scholar
• Efficacy and safety of OBE2109 in subjects with heavy menstrual bleeding associated with uterine fibroids (PRIMROSE 2). Available from: https://clinicaltrials.gov/ct2/show/NCT03070951?view=record ClinicalTrials.gov Identifier: NCT03070951. Accessed 414, 2019.
   Google Scholar
• A study to assess the efficacy and safety of OBE2109 in subjects with endometriosis (EDELWEISS). Available from: https://clinicaltrials.gov/ct2/show/NCT02778399?view=record ClinicalTrials.gov Identifier: NCT02778399. Accessed 414, 2019.
   Google Scholar
• Lamb YN. Elagolix: first global approval. Drugs. 2018;78(14):1501–1508. doi:10.1007/s40265-018-0977-430194661
   PubMed Web of Science ®Google Scholar
• Melis GB, Neri M, Corda V, et al. Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol. 2016;12(5):581–588. doi:10.1517/17425255.2016.117131627021205
   PubMed Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi:10.1056/NEJMoa170008928525302
   PubMed Web of Science ®Google Scholar
• Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–7485. doi:10.1021/jm800645419006286
   PubMed Web of Science ®Google Scholar
• Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–551. doi:10.1210/jc.2008-169519033369
   PubMed Web of Science ®Google Scholar
• Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. doi:10.1210/jc.2016-384528323948
   PubMed Web of Science ®Google Scholar
• Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2018;1–9.30168904
   PubMed Web of Science ®Google Scholar
• Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152–160.e4. doi:10.1016/j.fertnstert.2017.05.00628579415
   PubMed Web of Science ®Google Scholar
• Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132(5):1252–1264. doi:10.1097/AOG.000000000000293330303923
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Available from: https://clinicaltrials.gov/ct2/show/NCT02654054?view=record ClinicalTrials.gov Identifier: NCT02654054. Accessed 422, 2019.
   Google Scholar
• Efficacy and safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women (Replicate study). Available from: https://clinicaltrials.gov/ct2/show/record/NCT02691494?view=record ClinicalTrials.gov Identifier: NCT02691494. Accessed 422, 2019.
   Google Scholar
• Carr B, Bradley L, Al-Hendy A, et al. Elagolix treatment in women with heavy menstrual bleeding-associated with uterine fibroids: efficacy and safety results from two double-blind, randomized, placebo-controlled Phase 3 studies. J Minim Invasive Gynecol. 2018;25(7):S88. doi:10.1016/j.jmig.2018.09.178
   Google Scholar
• AbbVie News Center. AbbVie presents positive phase 3 data demonstrating investigational elagolix reduces heavy menstrual bleeding in women with uterine fibroids at 2018 AAGL global congress. 11 14, 2018 Available from: https://news.abbvie.com/news/press-releases/abbvie-presents-positive-phase-3-data-demonstrating-investigational-elagolix-reduces-heavy-menstrual-bleeding-in-women-with-uterine-fibroids-at-2018-aagl-global-congress.htm Accessed 422, 2019.
   Google Scholar
• An extension study to evaluate the efficacy and safety of elagolix in premenopausal women with heavy menstrual bleeding associated with uterine fibroids. ClinicalTrials.gov Identifier: NCT02925494. Available from: https://clinicaltrials.gov/ct2/show/NCT02925494?view=record Accessed 422, 2019.
   Google Scholar
• AbbVie News Center. AbbVie announces positive topline results from Phase 3 extension study evaluating investigational elagolix in women with uterine fibroids. 8 22, 2018 Available from: https://news.abbvie.com/news/press-releases/abbvie-announces-positive-topline-results-from-phase-3-extension-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids.htm Accessed 422, 2019.
   Google Scholar
• Long-term safety and efficacy of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Available from: https://clinicaltrials.gov/ct2/show/NCT03271489?view=record ClinicalTrials.gov Identifier: NCT03271489. Accessed 422, 2019.
   Google Scholar
• A study to evaluate the safety and efficacy of elagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Available from: https://clinicaltrials.gov/ct2/show/NCT03886220?view=record ClinicalTrials.gov Identifier: NCT03886220. Accessed 422, 2019.
   Google Scholar
• Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–160. doi:10.1097/AOG.000000000000267529889764
   PubMed Web of Science ®Google Scholar
• Hornstein MD, Surrey ES, Weisberg GW, Casino LA; Lupron Add-Back Study Group. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998;91(1):16–24. doi:10.1016/s0029-7844(97)00620-09464714
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–1351. doi:10.1177/193371911454984825249568
   PubMed Web of Science ®Google Scholar
• Coyne KS, Soliman AM, Margolis MK, Thompson CL, Chwalisz K. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. Curr Med Res Opin. 2017;33(2):193–200. doi:10.1080/03007995.2016.124838227733082
   PubMed Web of Science ®Google Scholar